Sponsor:
UCLA
Code:
NCT03860857
Conditions
Alzheimer Disease
Cognitive Impairment
Cognitive Decline
Eligibility Criteria
Sex: All
Age: 60+
Healthy Volunteers: Accepted
Interventions
Amyloid PET scan
Tau PET scan using MK-6240
Neurocognitive testing
MRI
Brief summary:
Conditions
Alzheimer Disease
Cognitive Impairment
Cognitive Decline
Study ID
NCT03860857
Start date
May 1, 2018
Status verified date
Jan, 2026
Completion date
Dec 22, 2027
Anticipated
Primary completion date
Dec 22, 2026
Anticipated
Eligibility Criteria
Sex: All
Age: 60+
Healthy Volunteers: Accepted
Enrollment
300 participants
Anticipated
Allocation
Non randomized
Intervention Model
Parallel Assignment
Primary purpose
Health Services Research
Arms
experimental: Age 60-65 ApoE e4+
experimental: Age 66-70 ApoE e4-
experimental: Age 66-70 ApoE e4+
experimental: Age 71-75 ApoE e4-
experimental: Age 71-75 ApoE e4+
experimental: Age 76-80 ApoE e4-
experimental: Age 76-80 ApoE e4+
experimental: Age 81+ ApoE e4-
experimental: Age 81+ ApoE e4+
Interventions
Amyloid PET scan
Tau PET scan using MK-6240
Neurocognitive testing
MRI
Primary outcome measure
Central contacts
Locations
University of California, Irvine
Recruiting
Irvine, California, United States, 92697
Contacts
Principal Investigator:
Michael A Yassa, PhD
Sponsor
University of California, Irvine
Last update posted
Jan 23, 2026
Last verified
Jan, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, Irvine on 2026-01-23.